Designer cathinones-An emerging class of novel recreational drugs

Forensic Science International

Volumn 231, Issue 1-3, 2013, Pages 42-53

  Zawilska, Jolanta B ^a   Wojcieszak, Jakub ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Bath salts; Cathinones; Mephedrone; Methylenedioxypyrovalerone; Novel psychoactive drugs

Indexed keywords

4' METHYLMETHCATHINONE; BENZODIAZEPINE DERIVATIVE; CATHINONE; DIAZEPAM; DROPERIDOL; FENTANYL; HALOPERIDOL; LABETALOL; LORAZEPAM; METHCATHINONE; METHYLONE; MIDAZOLAM; NORPSEUDOEPHEDRINE; PERPHENAZINE; PHENYTOIN; PROMETHAZINE; PROPOFOL; PYROVALERONE; RECREATIONAL DRUG; RISPERIDONE;

AGGRESSION; AGITATION; ANXIETY; AUTOPSY; CARDIOVASCULAR DISEASE; CATHA EDULIS; COGNITIVE DEFECT; DEHYDRATION; DRUG DEPENDENCE; DRUG TOLERANCE; FATALITY; FORENSIC TOXICOLOGY; GASTROINTESTINAL DISEASE; HALLUCINATION; HEART PALPITATION; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INSOMNIA; KIDNEY FAILURE; LEARNING; LIVER FAILURE; LOCOMOTION; MEMORY; MENTAL DISEASE; METABOLISM; MULTIPLE DRUG ABUSE; NEUROLOGIC DISEASE; NONHUMAN; PARANOIA; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; REINFORCEMENT; REVIEW; RHABDOMYOLYSIS; SUBSTANCE ABUSE; SUICIDE; TACHYCARDIA; THORAX PAIN; WITHDRAWAL SYNDROME;

EID: 84878890238     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2013.04.015     Document Type: Review

References (134)

1. Corazza O., Demetrovics Z., van den Brink W., Schifano F. 'Legal highs' an inappropriate term for 'novel psychoactive drugs' in drug prevention and scientific debate. Int. J. Drug Policy 2013, 24:82-83.
2. European Monitoring Centre for Drugs and Drug Addiction, Synthetic cathinones, (retrieved 2.10.12). http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cathinones.
3. European Monitoring Centre for Drugs and Drug Addiction, EU drug market report, a strategic analysis, (retrieved 23.02.13). http://www.emcdda.europa.eu/publications/joint-publications/drug-markets.
4. Adebamiro A., Perazella M.A. Recurrent acute kidney injury following bath salts intoxication. Am. J. Kidney Dis. 2012, 59:273-275.
5. McGraw M., McGraw L. Bath salts: not as harmless as they sound. J. Emerg. Nurs. 2012, 39:582-588.
6. Zuba D., Byrska B. Prevalence and co-existence of active components of 'legal highs'. Drug Test. Anal. 2012, 10.1002/dta.1365.
7. Ayres T.C., Bond J.W. A chemical analysis examining the pharmacology of novel psychoactive substances freely available over the Internet and their impact on public (ill)health. Legal highs or illegal highs?. BMJ Open 2012, 2. (pii: e000977).
8. Brandt S.D., Sumnall H.R., Measham F., Cole J. Analyses of second-generation 'legal highs' in the UK: initial findings. Drug Test. Anal. 2010, 2:377-382.
9. Davies S., Wood D.M., Smith G., Button J., Ramsey J., Archer R., Holt D.W., Dargan P.I. Purchasing 'legal highs' on the Internet-is there consistency in what you get?. QJM 2010, 103:489-493.
10. European Monitoring Centre for Drugs and Drugs Addiction, The state of the drugs problem in Europe, Annual Report 2010, pp. 91-95, (retrieved 15.4.11). http://www.emcdda.europa.eu/attachements.cfm/att_120104_EN_EMCDDA_AR2010_EN.pdf.
11. Hillebrand J., Olszewski D., Sedefov R. Legal highs on the Internet. Subst. Use Misuse 2010, 45:330-340.
12. Schmidt M.M., Sharma A., Schifano F., Feinmann C. "Legal highs" on the net-Evaluation of UK-based Websites, products and product information. Forensic Sci. Int. 2010, 206:92-97.
13. Vardakou I., Pistos C., Spiliopoulou Ch. Drugs for youth via Internet and the example of mephedrone. Toxicol. Lett. 2011, 201:191-195.
14. Walsh C. Drugs, the Internet and change. J. Psychoactive Drugs 2011, 43:55-63.
15. Schifano F., Albanese A., Fergus S., Stair J.L., Deluca P., Corazza O., Davey Z., Cockery J., Seemann H., Scherbaum N., Farre' M., Torrens M., Demetrovics Z., Ghodse A.H., Psychonaut Web Mapping, ReDNet Research Groups Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology (Berl.) 2011, 214:593-602.
16. Winstock A.R., Marsden J., Mitcheson L. What should be done about mephedrone?. BMJ 2010, 340:c1605.
17. Zawilska J.B. 'Legal highs'-new players in the old drama. Curr. Drug Abuse Rev. 2011, 4:122-130.
18. Brandt S.D., Freeman S., Sumnall H.R., Measham F., Cole J. Analysis of NRG "Legal highs" in the UK: identification and formation of novel cathinones. Drug Test. Anal. 2011, 3:569-575.
19. De Paoli G., Maskell P.D., Pounder D.J. Naphyrone: analytical profile of the new "legal high" substitute for mephedrone. J. Forensic Legal Med. 2011, 18:93.
20. Durham M. Ivory wave: the next mephedrone. Emerg. Med. J. 2011, 28:1059-1060.
21. Westphal F., Junge T., Rosner P., Sonnichsen F., Schuster F. Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: a designer drug with alpha-pyrrolidinophenone structure. Forensic Sci. Int. 2009, 190:1-8.
22. Uchiyama N., Kikura-Hanajiri R., Kawahara N., Goda Y. Analysis of designer drugs detected in the products purchased in fiscal year 2006. Yakugaku Zasshi. 2008, 128:1499-1505. (in Japanese).
23. Kikura-Hanajiri R., Uchiyama N., Goda Y. Survey of current trends in the abuse of psychotropic substances and plants in Japan. Leg. Med. 2011, 13:109-115.
24. EMCDDA, Europol 2011 Annual Report on the implementation of Council Decision 2005/387/JHA, (retrieved 6.12.12). http://www.emcdda.europa.eu/publications/implementation-reports/2011.
25. Hassan N.A., Gunaid A.A., Murray-Lyon I.M. Khat (Catha edulis): health aspects of khat chewing. East Mediterr. Health J. 2007, 13:706-718.
26. Brenneisen R., Fisch H.U., Koelbing U., Geisshüsler S., Kalix P. Amphetamine-like effects in humans of the khat alkaloid cathinone. Br. J. Clin. Pharmacol. 1990, 30:825-828.
27. Kalix P. Pharmacological properties of the stimulant khat. Pharmacol. Ther. 1990, 48:397-416.
28. Al-Habori M. The potential adverse effects of habitual use of Catha edulis (khat). Expert Opin. Drug Saf. 2005, 4:1145-1154.
29. Balint E.E., Falkay G., Balint G.A. Khat-a controversial plant. Wien. Klin. Wochenschr. 2009, 121:604-614.
30. Colzato L.S., Ruiz M.J., van den Wildenberg W.P., Hommel B. Khat use is associated with impaired working memory and cognitive flexibility. PLoS ONE 2011, 6:e20602.
31. Gibbons S., Zloh M. An analysis of 'legal high' mephedrone. Bioorg. Med. Chem. Lett. 2010, 20:4135-4139.
32. Deluca P., Davey Z., Corazza O., Di Furia L., Farre M., Flesland L.H., Mannonen M., Majava A., Peltoniemi T., Pasinetti M., Pezzolesi C., Scherbaum N., Siemann H., Skutle A., Torrens M., van der Kreeft P., Iversen E., Schifano F. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 39:221-226.
33. Department of Justice Drug Enforcement Administration Schedules of controlled substances: temporary placement of three synthetic cathinones into Schedule I. Fed. Regist. 2011, 76:65371-65375.
34. Marinetti L.J., Antonides H.M. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J. Anal. Toxicol. 2013, 10.1093/bks136.
35. Spiller H.A., Ryan M.L., Weston R.G., Jansen J. Clinical experience with analytic confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin. Toxicol. (Phila.) 2011, 49:499-505.
36. Kriikku P., Wilhelm L., Schwarz O., Rintatalo J. New designer drug of abuse: 3,4-methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic Sci. Int. 2011, 210:195-200.
37. McElrath K., O'Neill C. Experiences with mephedrone pre- and post-legislative control: perceptions of safety and sources of supply. Int. J. Drug Policy 2011, 22:120-127.
38. European Monitoring Centre for Drugs and Drug Addiction, Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances, (retrieved 8.11.12). http://www.emcdda.europa.eu/attachements.cfm/att_116646_EN_TDAK11001ENC_WEB-OPTIMISED%20FILE.pdf.
39. Cosbey S.H., Peters K.L., Quinn A., Bentley A. Mephedrone (methylmethcathinone) in toxicology casework: a Northern Ireland perspective. J. Anal. Toxicol. 2013, 10.1093/jat/bsk094.
40. Dargan P.I., Albert S., Wood D.M. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 2010, 103:875-879.
41. Dargan P.I., Sedefov R., Gallegos A., Wood D.M. The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test. Anal. 2011, 3:454-463.
42. Winstock A.R., Mitcheson L.R., Deluca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.
43. Lea T., Reynolds R., De Wit J. Mephedrone use among same-sex attracted young people in Sydney, Australia. Drug Alcohol Rev. 2011, 30:338-340.
44. Brunt T.M., Poortman A., Niesink R.J., van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. J. Psychopharmacol. 2011, 25:1543-1547.
45. Carhart-Harris R.L., King L.A., Nutt D.J. A web-based survey on mephedrone. Drug Alcohol Depend. 2011, 118:19-22.
46. Deluca P., Schifano F., Davey Z., Corazza O., Di Furia L., Farre M., Flesland L., Mannonen M., Majava A., Mineli V., Pagani S., Peltoniemi T., Scherbaum N., Siemann H., Skutle A., Torrens M., Pezzolesi C., van der Kreeft P., Psychonaut Web Mapping Research Group Mephedrone Report 2009, http://www.psychonautproject.eu/documents/reports/Mephedrone.pdf (retrieved 4.10.12).
47. Van Hout M.C., Bingham T. "A costly turn on": patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. Int. J. Drug Policy 2012, 23:188-197.
48. Van Hout M.C., Brennan R. 'Heads held high': an exploratory study of legal highs in pre-legislation Ireland. J. Ethn. Subst. Abuse 2011, 10:256-272.
49. Winstock A., Mitcheson L., Marsden J. Mephedrone: still available and twice the price. Lancet 2010, 376(9752):1537.
50. Wood D.M., Hunter L., Measham F., Dargan P.I. Limited use of novel psychoactive substances in South London nightclubs. QJM 2012, 105:959-964.
51. Info.sheet: MDPV, (retrieved 8.11.12). http://crew2000.org.uk/.
52. Info.sheet: Naphyrone, (retrieved 8.11.12). http://crew2000.org.uk/.
53. Forrester M.B. Synthetic cathinone exposures reported to Texas Poison Centers. Am. J. Drug Alcohol Abuse 2012, 38:609-617.
54. James D., Adams R.D., Spears R., Cooper G., Lupton D.J., Thompson J.P., Thomas S.H., on behalf of the National Poisons Information Service Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg. Med. J. 2011, 28:686-689.
55. Winstock A., Mitcheson L., Ramsey J., Davies S., Puchnarewicz M., Marsden J. Mephedrone: use, subjective effects and health risks. Addiction 2011, 106:1991-1996.
56. Vardakou I., Pistos C., Dona A., Spiliopoulou C., Athanaselis S. Naphyrone: a "legal high" not legal any more. Drug Chem. Toxicol. 2012, 35:467-471.
57. Ross E.A., Watson M., Goldberger B. "Bath salts" intoxication. N. Engl. J. Med. 2012, 365:967.
58. Karila L., Reynaud M. GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test. Anal. 2011, 3:552-559.
59. Khreit O.I.G., Grant M.H., Zhong T., Henderson C., Watson D.G., Sutcliffe O.B. Elucidation of the phase I and phase II metabolic pathways of (±)-4'-methylmethcathinone (4-MMC) and (±)-4'-(trifluoromethyl(methcathinone)) (4-TFMMC) in rat liver hepatocytes using LC-MS and LC-MC. J. Pharm. Biomed. Anal. 2013, 72:177-185.
60. Locos O., Reynolds D. The characterization of 3,4-dimethylmethcathinone (3,4-DMMC). J. Forensic Sci. 2012, 57:1303-1306.
61. Mueller D.M., Rentsch K.M. Generation of metabolites by an automated online metabolism method using human liver microsomes with subsequent identification by LC-MS(n), and metabolism of 11 cathinones. Anal. Bioanal. Chem. 2012, 402:2141-2151.
62. Meyer M.R., Du P., Schuster F., Maurer H.H. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxypyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J. Mass Spectrom. 2010, 45:1426-1442.
63. Meyer M.R., Wilhelm J., Peters F.T., Maurer H.H. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal. Bioanal. Chem. 2010, 397:1225-1233.
64. Meyer M.R., Vollmar C., Schwaninger A.E., Wolf E., Maurer H.H. New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoro-methcathinone: studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC-high-resolution MS and their detectability in urine. J. Mass Spectrom. 2012, 47:253-262.
65. Ojanpera A., Heikman P.K., Rasanen I.J. Urine analysis of 3,4-methylene-dioxypyrovalerone in opioid-dependent patients by gas chromatography-mass spectrometry. Ther. Drug Monit. 2011, 33:257-263.
66. Sørensen L.K. Determination of cathinones and related ephedrines in forensic whole-blood samples by liquid-chromatography-electrospray tandem mass spectrometry. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2011, 879:727-736.
67. Pedersen A.J., Reitzel L.A., Johansen S.S., Linnet K. In vitro metabolism studies on mephedrone and analysis of forensic cases. Drug Test. Anal. 2012, 10.1002/dta.1369.
68. Strano-Rossi S., Cadwallader A.B., de la Torre X., Botrè F. Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2011, 24:2706-2714.
69. Simmler L.D., Buser T.A., Donzelli M., Schramm Y., Dieu L.H., Huwyler J., Chaboz S., Hoener M.C., Liechti M.E. Pharmacological characterization of designer cathinones in vitro. Br. J. Pharmacol. 2013, 168:458-470.
70. Baumann M.H., Ayestas M.A., Partilla J.S., Sink J.R., Shulgin A.T., Daley P.F., Brandt S.D., Rothman R.B., Ruoho R.A.E., Cozzi N.V. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012, 37:1192-1203.
71. Baumann M.H., Partilla J.S., Lehner K.R., Thorndike E.B., Hoffman A.F., Holy M., Rothman R.B., Goldberg S.R., Lupica C.R., Sitte H.H., Brandt S.D., Tella S.R., Cozzi N.V., Schindler C.W. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology 2013, 38:552-562.
72. López-Arnau R., Martínez-Clemente J., Pubill D., Escubedo E., Camarasa J. Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br. J. Pharmacol. 2012, 167:407-420.
73. Martínez-Clemente J., Escubedo E., Pubill D., Camarasa J. Interaction of mephedrone with dopamine and serotonin targets in rats. Eur. Neuropsychopharmacol. 2012, 22:231-236.
74. Cozzi N.V., Sievert M.K., Shulgin A.T., Jacob P., Ruoho A.E. Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur. J. Pharmacol. 1999, 381:63-69.
75. Hadlock G.C., Webb K.M., McFadden L.M., Chu P.W., Eblis J.D., Allen S.C., Andrenyak D.M., Vieira-Brock P.L., German C.L., Conrad K.M., Hoonakker A.J., Gibb J.W., Wilkins D.G., Hanson G.R., Fleckenstein A.E. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J. Pharmacol. Exp. Ther. 2011, 339:530-536.
76. Nagai F., Nonaka R., Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur. J. Pharmacol. 2007, 559:132-137.
77. Kehr J., Ichinose F., Yoshitake S., Goiny M., Sievertsson T., Nyberg F., Yoshitake T. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br. J. Pharmacol. 2011, 164:1949-1958.
78. Cozzi N.V., Foley K.F. Methcathinone is a substrate for the serotonin uptake transporter. Pharm. Technol. 2003, 93:219-225.
79. Meltzer P.C., Butler D., Deschamps J.R., Madras B.K. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J. Med. Chem. 2006, 49:1420-1432.
80. Cameron K.N., Kolanos R., Solis E., Glennon R.A., De Felice L.J. Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. Br. J. Pharmacol. 2013, 168:1750-1757.
81. Motbey C.P., Hunt G.E., Bowen M.T., Artissm S., McGregor I.S. Mephedrone (4-methylmethcathinone, 'meow'): acute behavioural effects and distribution of Fos expression in adolescent rats. Addict. Biol. 2012, 17:409-422.
82. den Hollander B., Rozov S., Linden A.M., Uusi-Oukari M., Ojanperä I., Korpi E.R. Long-term cognitive and neurochemical effects of "bath salt" designer drugs methylone and mephedrone. Pharmacol. Biochem. Behav. 2012, 103:501-509.
83. Lisek R., Xu W., Yuvasheva E., Chiu Y.T., Reitz A.B., Liu-Chen L.Y., Rawls S.M. Mephedrone ('bath salt') elicits conditioned place preference and dopamine-sensitive motor activation. Drug Alcohol Depend. 2012, 126:257-262.
84. Marusich J.A., Grant K.R., Blough B.E., Wiley J.L. Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice. Neurotoxicology 2012, 33:1305-1313.
85. Motbey C.P., Karanges E., Li K.M., Wilkinson S., Winstock A.R., Ramsay J., Hicks C., Kendig M.D., Wyatt N., Callaghan P.D., McGregor I.S. Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion. PLoS ONE 2012, 7:e45473.
86. Shortall S.E., Macerola A.E., Swaby R.T., Jayson R., Korsah C., Pillidge K.E., Wigmore P.M., Ebling F.J., Green A.R., Fone K.C., King M.V. Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. Eur. Neuropsychopharmacol. 2012, 10.1016/j.euroneuro.2012.09.005.
87. Varner K.J., Daigle K., Weed P.F., Lewis P.B., Mahne S.E., Sankaranarayanan A., Winsauer P.J. Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs of abuse in rats. Psychopharmacology (Berl.) 2013, 225:675-685.
88. Wright M.J., Vandewater S.A., Angrish D., Dickerson T.J., Taffe M.A. Mephedrone (4-methylmethcathinone, 4MMC) and d-methamphetamine improve visuo-spatial associative memory, but not spatial working memory, in rhesus macaques. Br. J. Pharmacol. 2012, 10.1111/j.1476-5381.2012.02091.x.
89. Watterson L.R., Kufahl P.R., Nemirovsky N.E., Sewalia K., Grabenauer M., Thomas B.F., Marusich J.A., Wegner S., Olive M.F. Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict. Biol. 2012, 10.1111/j.1369-1600.2012.00474.x.
90. Aarde S.M., Angrish D., Barlow D.J., Wright M.J., Vandewater S.A., Creehan K.M., Houseknecht K.L., Dickerson T.J., Taffe M.A. Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. Addict. Biol. 2013, 10.1111/adb.12038.
91. Antonowicz J.L., Metzger A.K., Ramanujam S.L. Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen. Hosp. Psychiatry 2011, 33:640.e5-640.e6.
92. Boulanger-Gobeil C., St-Onge M., Laliberté M., Auger P.L. Seizures and hyponatremia related to ethcathinone and methylone poisoning. J. Med. Toxicol. 2012, 8:59-61.
93. Winder G.S., Stern N., Hosanagar A. Are "bath salts" the next generation of stimulant abuse?. J. Subst. Abuse Treat. 2013, 44:42-45.
94. Borek H.A., Holstege C.P. Hyperthermia and multiorgan failure after abuse of "bath salts" containing 3,4-methylenedioxypyrovalerone. Ann. Emerg. Med. 2012, 60:103-105.
95. Lusthof K.J., Oosting R., Maes A., Verschraagen M., Dijkhuizen A., Sprong A.G. A case of extreme agitation and death after the use of mephedrone in The Netherlands. Forensic Sci. Int. 2011, 206:393-395.
96. Murray B.L., Murphy C.M., Beuhler M.C. Death following recreational use of designer drug "bath salts" containing 3,4-methylenedioxypyrovalerone (MDPV). J. Med. Toxicol. 2012, 8:69-75.
97. Rojek S., Kłys M., Strona M., Maciów M., Kula K. "Legal highs"-toxicity in the clinical and medico-legal aspect as exemplified by suicide with bk-MBDB administration. Forensic Sci. Int. 2012, 222:e1-e6.
98. Young A.C., Schwarz E.S., Velez L.I., Gardner M. Two cases of disseminated intravascular coagulation due to "bath salts" resulting in fatalities, with laboratory confirmation, Am. J. Emerg. Med. 2013, 31:445e3-445e5.
99. Levine M., Levitan R., Skolnik A. Compartment syndrome after "bath salts" use: a case series. Ann. Emerg. Med. 2013, 61:480-483.
100. Mugele J., Nañagas K.A., Tormoehlen L.M. Serotonin syndrome associated with MDPV use: a case report. Ann. Emerg. Med. 2012, 60:100-103.
101. Wood D.M., Greene S.L., Dargan P.I. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg. Med. J. 2010, 28:280-282.
102. Regan L., Mitchelson M., Macdonald C. Mephedrone toxicity in a Scottish emergency department. Emerg. Med. J. 2011, 28:1055-1058.
103. Wood D.M., Davies S., Greene S.L., Button J., Holt D.W., Ramsey J., Dargan P.I. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin. Toxicol. (Phila.) 2010, 48:924-927.
104. Centers for Disease Control and Prevention (CDC) Emergency department visits after use of a drug sold as "bath salts"-Michigan, November 13, 2010-March 31, 2011. MMWR. Morb. Mortal. Wkly. Rep. 2011, 60:624-627.
105. Murphy C.M., Dulaney A.R., Beuhler M.C., Kacinko S. "Bath salts" and "plant food" products: the experience of one regional US Poison Center. J. Med. Toxicol. 2013, 9:42-48.
106. Corkery J.M., Schifano F., Ghodse A.H. Mephedrone-related fatalities in the United Kingdom: contextual, clinical and practical issues. Pharmacology 2012, 17:355-380. http://cdn.intechopen.com/pdfs/32134/InTech-Mephedrone_related_fatalities_in_the_united_kingdom_contextual_clinical_and_practical_issues.pdf (retrieved 9.12.12).
107. Sikk K., Haldre S., Aquilonius S.-M., Taba P. Manganese-induced Parkinsonism due to ephedrone use. Parkinsons Dis. 2011, 865319.
108. Derungs A., Schietzel S., Meyer M.R., Maurer H.H., Krähenbühl S., Liechti M.E. Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylpyrovalerone). Clin. Toxicol. 2011, 49:691-693.
109. Goshgarian A.M., Caplan J.P. Bath salt abuse: neuropsychiatric effects of cathinone derivatives. Psychosomatics 2011, 52:592-593.
110. Kyle P.B., Iverson R.B., Gajagowni R.G., Spencer L. Illicit bath salts: not for bathing. J. Miss. State Med. Assoc. 2011, 52:375-377.
111. Penders T.M., Gestring R. Hallucinatory delirium following use of MDPV: "bath salts". Gen. Hosp. Psychiatry 2011, 33:525-526.
112. Penders T.M., Gestring R.E., Vilensky D.A. Excited delirium following use of synthetic cathinones (bath salts). Gen. Hosp. Psychiatry 2012, 34:647-650.
113. Freeman T.P., Morgan C.J., Vaughn-Jones J., Hussain N., Karimi K., Curran H.V. Cognitive and subjective effects of mephedrone and factors influencing use of a 'new legal high'. Addiction 2012, 107:792-800.
114. Dorairaj J.J., Healy C., McMenamin M., Eadie P.A. The untold truth about "bath salt" highs: a case series demonstrating local tissue injury. J. Plast. Reconstr. Aesthet. Surg. 2012, 65:e37-e41.
115. Russo R., Marks N., Morris K., King H., Gelvin A., Rooney R. Life-treating necrotizing fasciitis due to "bath salts" injection. Orthopedics 2012, 25:e124-e127.
116. Schifano F., Corkery J., Ghodse A.H. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, "meow meow") in the United Kingdom. J. Clin. Psychopharmacol. 2012, 32:710-714.
117. Dickson A.J., Vorce S.P., Levine B., Past M.R. Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J. Anal. Toxicol. 2010, 34:162-168.
118. Aromatario M., Bottoni E., Santoni M., Ciallella C. New "Lethal highs": a case of a deadly cocktail of GHB and mephedrone. Forensic Sci. Int. 2012, 223:e38-e41.
119. Adamowicz P., Tokarczyk B., Stanaszek R., Slopianka M. Fatal mephedrone intoxication-a case report. J. Anal. Toxicol. 2013, 37:37-42.
120. Maskell P.D., De Paoli G., Seneviratne C., Pounder D.J. Mephedrone (4-methylmethcathinone)-related deaths. J. Anal. Toxicol. 2011, 35:188-191.
121. Cawrse B.M., Levine B., Jufer R.A., Fowler D.R., Vorce S.P., Dickson A.J., Holler J.M. Distribution of methylone in four postmortem cases. J. Anal. Toxicol. 2012, 36:434-439.
122. Warrick B.J., Wilson J., Hedge M., Freeman S., Leonard K., Aaron C. Lethal serotonin syndrome after methylone and butylone ingestion. J. Med. Toxicol. 2012, 8:65-68.
123. Wikström M., Thelander G., Nyström I., Kronstrand R. Two fatal intoxications with the new designer drug methedrone (4-methoxymethcathinone). J. Anal. Toxicol. 2010, 34:594-598.
124. Prosser J.M., Nelson L.S. The toxicology of bath salts: a review of synthetic cathinones. J. Med. Toxicol. 2012, 8:33-42.
125. Sammler E.M., Foley P.L., Lauder G.D., Wilson S.J., Goudzie A.R., O'Riordan J.I. A harmless high?. Lancet 2010, 376(9742):742.
126. Wood D.M., Davies S., Puchnarewicz M., Button J., Archer R., Ovaska H., Ramsey J., Lee T., Holt D.W., Dargan P.I. Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J. Med. Toxicol. 2010, 6:327-330.
127. Thornton S.L., Gerona R.R., Tomaszewski C.A. Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J. Med. Toxicol. 2011, 8:310-313.
128. Fröhlich S., Lambe E., O'Dea J. Acute liver failure following recreational use of psychotropic "head shop" compounds. Ir. J. Med. Sci. 2011, 180:263-264.
129. Nicholson P.J., Quinn M.J., Dodd J.D. Headshop heartache: acute mephedrone 'meow' myocarditis. Heart 2010, 96:2051-2052.
130. Maan Z.N., D'Souza A.R. Spontaneous subcutaneous emphysema associated with mephedrone usage. Ann. R. Coll. Surg. Engl. 2012, 94:e38-e40.
131. Regunath H., Ariyamuthu V.K., Dalal P., Misra M. Bath salt intoxication causing acute kidney injury requiring hemodialysis. Hemodial. Int. 2012, 16(Suppl. 1):S47-S49.
132. Sharma T.R., Iskandar J.W., Ali R., Shah U.R. Bath salts-induced delirium and brief psychotic episode in an otherwise health young man. Prim. Care Companion CNS Disord. 2012, 14. (pii: PCC110.1224).
133. Striebel J.M., Pierre J.M. Acute psychotic sequelae of "bath salts". Schizophr. Res. 2011, 133:259-260.
134. Joksovic P., Mellos N., van Wattum P.J., Chiles C. "Bath salts"-induced psychosis and serotonin toxicity. J. Clin. Psychiatry 2012, 73:1125.